Abstract Historically, entities with a vested interest in a product that critics have suggested is harmful have consistently used research to back their claims that the product is safe. Prominent examples are: tobacco, lead, bisphenol A, and atrazine. Research literature indicates that about 80-90% of studies with industry affiliation found no harm from the product, while only about 10-20% of studies without industry affiliation found no harm. In parallel to other historical debates, recent studies examining a possible relationship between mercury (Hg) exposure and autism spectrum disorder (ASD) show a similar dichotomy. Studies sponsored and supported by industry or entities with an apparent conflict of interest have most often shown no evidence of harm or no ''consistent'' evidence of harm, while studies without such affiliations report positive evidence of a Hg/autism association. The potentially causal relationship between Hg exposure and ASD differs from other toxic products since there is a broad coalition of entities for whom a conflict of interest arises. These include influential governmental public health entities, the pharmaceutical industry, and even the coal burning industry. This review includes a systematic literature search of original studies on the potential relationship between Hg and ASD from 1999 to August 2015, finding that of the studies with public health and/or industry affiliation, 86% reported no relationship between Hg and ASD. However, among studies without public health and/or industry affiliation, only 21% find no relationship between Hg and ASD. The discrepancy in these results suggests a bias indicative of a conflict of interest.
Introduction
A possible link between exposure to mercury (Hg) and autism spectrum disorder (ASD) is a recent example of a heated debate over the association between a pervasive toxic exposure and a prevalent and devastating diagnosis. The heated debate began in the late 1990s, when it was suggested that exposure to Hg in vaccines was a risk factor for ASD (Halsey 1999) . In this case, as in those before it, whenever there has been a possible link between illness and a toxic exposure, there has been heated debate characterized by adamant denial.
Denial of a toxicant in disease causation can be attributed in part and firstly, to a natural inclination to resist unpleasant theories. A historical illustration of this was acrodynia (also known as Pink Disease). This almost forgotten disease, mostly affecting infants and young children, is a well-studied example of human Hg poisoning (Bjørklund 1995) . Hg as the cause of acrodynia was first suggested in 1846, and again in 1922 (Hanson and Pleva 1991) . Josef Warkany and Donald M. Hubbard (1948) 
from the United States (US) demonstrated Hg involvement in 25
Mark R. Geier mgeier@comcast.net 1 out of 28 cases of acrodynia in 1948. When Hg-containing teething powders were withdrawn from the market in Australia in 1953 (followed later by the US), there was a dramatic fall in the incidence and mortality rate from acrodynia (Bjørklund 1995) . However, the role of Hg as the primary source of acrodynia was not universally accepted even as late as 1956 (Dathan and Harvey 1965) . Throughout these decades of heated debate, the science indicating that acrodynia was caused by Hg exposure was resisted because, as stated by a historian studying the social and medical aspects of the illness, ''poisoning was not a fashionable diagnosis'' (Dally 1997) .
Resistance to linking a toxic exposure to an illness can also result from a concern for liability. The responsibility for an illness or disability that results from a toxic product is borne by the industry that manufactures it, and resistance to a link between illness and an antecedent exposure is often driven by an industry that fears the consequences, since it is in their best interest to do so (Bridbord and Hanson 2009; Brownell and Warner 2009; Friedman and Richter 2005; Hayes 2004; McComas 2008; Ong and Glantz 2001; Sass 2006) . As a result, conflicts of interest enter these debates and the resulting discourse is often marred by misleading information, which, unfortunately, often includes misleading assertions concerning the state of scientific research.
Historically, entities with a vested interest in a product that critics have suggested is harmful have consistently used research to back their claims that a product is safe. Kelly Brownell and Kenneth Warner (2009) reviewed the issue of conflicts of interest in research. They concluded that industry manipulates research information to buy loyalty, instill doubt about criticisms, confuse the public, give ammunition to political allies, and stall or influence government action. This practice, as noted by Brownell and Warner (2009) and many other experts on the subject, continues to the present day (Barnoya and Glantz 2006; Brownell and Warner 2009; Kessler 2001; Mars and Ling 2008; Michaels 2008; Mooney 2006; Schick and Glantz 2007) . The following discussion of examples of research conflicts of interest starts with tobacco because much of what we have learned regarding the influencing or ''buying'' of scientists is from tobacco litigation.
Past and Current Examples of Research Conflict of Interest and Outside Influences Tobacco
The tobacco industry spent significant funds in their attempts to undermine the science with respect to a link between smoking and lung disease (including issues related to secondhand smoke), calling into question the research that showed harm from smoking (McGarity and Wagner 2008; Tong and Glantz 2007) . Evidence indicates that the industry paid prominent scientists to conduct studies with the intent of countering potentially damaging scientific evidence (Cummings et al. 2007) . Internal documents revealed that the industry devised a plan to become a major sponsor of medical research in the Draft Recommendations for Cigarette Manufacturers of 1953 (Brandt 2012) . According to Allan Brandt (2012) this ''call for new research'' was intended to: (1) give the impression that existing studies were inadequate or flawed, referring to them as ''junk'' science, and (2) to create uncertainty about the harm from tobacco while making the industry appear to be a committed participant in the scientific endeavor (Brownell and Warner 2009) . The industry developed research programs that offered funds directly to university-based scientists in order to enlist the support, and develop the financial dependence, of those scientists (Brandt 2012) .
Lead
Another example is lead (Pb) poisoning. Pb poisoned the environment for decades while being used in many products (gasoline, paint, and pipes) before action was taken. The first documented case of childhood Pb poisoning in the US was in 1914. By 1930, Pb paint was regulated or banned in most European countries. Nevertheless, the US lead industry fought federal and local regulation of its products and promoted its use for several more decades (Grist 2004) .
The toxicity of Pb was the subject of heated debate, and the debate was again marked by resistance, conflicts of interest, and misleading information. As reported by Kenneth Bridbord and David Hanson (2009) , the Pb industry used their public relations capabilities to advertise the benefits of their products to the general public while casting doubt on the possibility of harm associated with its use. This was achieved, ''…in large part, by being the primary supporter of research on health effects of lead and relying upon the scientists that it supported to communicate and interpret this research to the government and the public.'' (Bridbord and Hanson 2009, p. 1195) .
Industry pressure may have influenced policy-makers, because they pursued a strategy that focused on diagnosing children after they were poisoned (the effect) rather than identifying toxic sources (the cause), which in effect allowed children to be exposed to and poisoned by lead for years to come (Grist 2004) .
Methylmercury
Minamata disease provides another example of a heated debate about the link between toxicant exposure and the resulting diagnosis. Minamata disease was caused by methylmercury poisoning, where the putative source of the mercury (Hg) was methyl-Hg-cysteine from contaminated fish. The fish were contaminated with methylmercury from the dumping of mercury-tainted waste into water in Minamata, Japan by the Chisso Plant. The disease was attributed to many other causes: infection, explosions, etc., with some of the alternative theories being promoted by the Chisso Plant itself, the company ultimately found to be responsible for the exposure (Takeuchi et al. 1978) . Early studies conducted by the Chisso Plant found their industrial waste caused the disease (Smith 2014) ; however, that information was not published. In fact, even while knowing this information, the Chisso Plant funded research into alternative causes of the disease, other than its own waste (Encyclopedia of the Earth 2009).
Atrazine
Reports of conflicts of interest in research include the herbicide atrazine, which was banned in the European Union in 2004, but is still used in the US (European Commission 2004) . Tyrone Hayes (2004) found that financial sponsorship was a strong predictor of study outcome for atrazine research (p = 0.009). Thus funding sources varied for studies reporting adverse effects (including government and industry funding), but all of the studies that failed to detect adverse effects were funded by the manufacturer of atrazine.
Bisphenol A Similar to atrazine research, Frederick vom Saal and Claude Hughes (2005) , who studied bisphenol A (BPA), found that no BPA industry-funded studies have ever reported significant effects from low doses of BPA, although more than 90% of government-funded studies reported significant effects from low doses of BPA. Moreover, some of the industry-funded BPA studies that reported no significant effects used a strain of rats that was inappropriate for the study of estrogenic responses (vom Saal and Hughes 2005) .
Olestra
Similar results have been reported in food research. For example, among studies supportive of the fat substitute olestra, 80% were funded by the food industry; however, in contrast, only 21% of neutral studies and 11% of studies critical of olestra have been funded by the industry (Levine et al. 2003) . All authors affiliated with the maker of olestra have published studies that are supportive of olestra (Levine et al. 2003 ).
Conflicts of Interest in Mercury Exposure and Autism Research
Conflicts of interest in studies examining Hg exposure and the resulting risk of ASD have been noted (DeSoto and Hitlan 2010) . In parallel to other historical debates over potential toxicants and their resulting adverse effects, studies examining the Hg-autism link that were sponsored and supported by entities with apparent conflicts of interest, often show no evidence of harm or no ''consistent'' evidence of harm from Hg exposure, even in the most vulnerable subjects, human fetuses and infants.
For example, studies on Hg exposure from coal-burning plants conducted by researchers without industry affiliation consistently show that Hg exposure from coal burning is a significant risk factor for ASD (Blanchard et al. 2011; Palmer et al. 2006 Palmer et al. , 2009 Windham et al. 2006) . In contrast, Thomas Lewandowski and colleagues (2009) , researchers with industry affiliation, examined the relationship between Hg release in Texas and ASD and found different results. Lewandowski works for Gradient, a product defense consulting firm that has received substantial sums from companies to write reports defending products such as cigarettes and BPA (Keim 2007) . Lewandowski and colleagues (2009) concluded that Hg emissions are not ''consistently'' associated with ASD prevalence in Texas school districts.
Another example of such conflict of interest in research is found in studies conducted on the safety of RhoD immune globulin (RhoGAM). Different formulations of Thimerosal (49.55% Hg by weight)-containing RhoGAM were routinely administered to Rh-negative mothers in the US prior to 2002. Studies conducted by researchers without industry affiliations found significant increases in maternal Rh-negativity among children with neurodevelopmental disorders (NDs), including ASD (Geier and Geier 2007b; Geier et al. 2008; Holmes et al. 2003 Miles and T. Nicole Takahashi (2007) commenced and concluded that exposure to ethylmercury (or Thimerosal) from RhoGAM was not associated with ASD (Miles and Takahashi 2007) .
In ASD, the stakes for industry are particularly high, with millions of children affected globally (DeSoto and Hitlan 2010). As mentioned, more than one industry views this issue through the lens of their own potential culpability: the coal burning industry which expels mercury into the air and the pharmaceutical industry which uses Hg as a preservative in some vaccines. However, the issue of conflicts of interest in research that examines the relationship between Hg exposure and ASD is different from the typical toxic substances and products previously mentioned in that the public health sector, a powerful and influential global and governmental alliance, views this issue through the lens of its own potential culpability. According to internal documents, public health officials are concerned that negative information about Thimerosal (the Hg-based preservative used in some vaccines), if substantiated, might damage the vaccine program, in which the public health system has a vested interest as a result of its role in vaccine distribution and use (Association of American Physicians and Surgeons, Inc. 2005) . As reported by the United States Congressional Report of 2003 in regard to the issue of Thimerosal and ASD, ''Our public health agencies' failure to act is indicative of institutional malfeasance for self-protection and misplaced protectionism of the pharmaceutical industry.'' (Burton 2003) .
Additionally, one public health entity, the US Centers for Disease Control and Prevention (CDC), receives millions of dollars in industry gifts and funding, including substantial support from the pharmaceutical industry (Lenzer 2015; Smith et al. 2012 ). According to Jeanne Lenzer (2015) , numerous manufacturers give donations to the CDC through the CDC Foundation. For example, in 2012-2013 Janssen donated $1.5 million, and in 2011-2012 contributors included Merck ($915,149), Genzyme ($762,000), Sanofi-Aventis ($600,000), and Abbott Laboratories ($550,000) (Lenzer 2015; Smith et al. 2012 ). This significant financial relationship further amplifies the potential for conflict of interest on the part of the CDC.
The issue of conflict of interest in ASD can be illustrated by an examination of the published scientific literature. A systematic literature search of original studies from 1999 to August 2015 using the search terms ''autism and mercury'' reveals evidence of this bias. The results of this search are listed and briefly described in Tables 1 and 2. Table 1 shows the studies on Thimerosal (or mercury) and ASD which were sponsored or co-sponsored by those with public health, pharmaceutical industry, or coal-burning affiliation, that is, studies with an apparent conflict of interest. Table 2 shows the studies on Thimerosal (or mercury) and ASD that were conducted by independent researchers without public health or industry affiliation.
Similar to historical debates about other toxicants, the findings reveal, that research done with an apparent conflict of interest shows a bias toward the null hypothesis or ''no effect'' (i.e., no relationship between Hg and ASD). Specifically, of the studies with public health or industry affiliation, 86% (12/14) failed to reject the null hypothesis ( Table 1 ), concluding that there was ''no effect''. However, of the studies without public health or industry affiliation, only 21% (13/62) failed to reject the null hypothesis. In other words, about 80% of the studies without public health or industry affiliation found evidence of a relationship between Hg exposure and ASD (Table 2 ). The dramatic discrepancy in these results, 86 versus 21%, provides evidence of biased outcomes, indicative of a conflict of interest.
The Need for Transparency in Autism Research
As mentioned earlier, the stakes in the ASD debate are high. In the past two decades, there has been a dramatic increase in ASD rates. For example, in a study which examined the prevalence and characteristics of developmental disabilities over a 15-20 year time period, with specific focus on concurrent changes in ASD and intellectual disability prevalence (using data from a population-based developmental disabilities surveillance program for 8-year-olds in metropolitan Atlanta), scientists found a 269% increase from 4.2 per 1000 in 1996 to 15.5 per 1000 in 2010 (Van Naarden Braun et al. 2015) . ASD is considered to have reached epidemic proportions and is an issue of high national and international concern. The critical importance of this debate only heightens the urgent need for transparency in autism research.
Transparency in autism research, including access to research datasets used, would provide for the review and evaluation of studies and the partiality or impartiality which characterized them, and encourage a system of checks and balances. When study findings are deemed inaccurate and/or biased, transparency in autism research would allow for either confirmation or correction. For instance, in 2004, Patrick Ip and colleagues published a study comparing Hg levels in the blood and hair of both children with ASD and controls, reporting that there was no difference in mean Hg levels (Ip et al. 2004 ). However, other scientists noted that there did appear to be a significant difference in the mean Hg levels between the groups and subsequently requested the data. Upon re-analysis, the data revealed that there was indeed a significant difference in the mean mercury levels between children with ASD and controls (DeSoto and Hitlan 2007) . The authors of the re- Medicine, Sager 2004) . In her presentation, she presented crucial evidence on the comparative distribution and persistence of Hg in brain and blood following methyl-Hg and Thimerosal administration to infant monkeys mimicking the US childhood vaccine schedule of the 1990s by other investigators (Burbacher et al. 2005) . It was later discovered, (Burbacher et al. 2005) . As a consequence, in evaluating the relationship between Thimerosal exposure and ASD risk, the IOM was unable to consider accurate and true data as to the distribution and persistence of Hg in the monkey brain following Thimerosal administration mimicking the US childhood vaccine schedule of the 1990s.
Examples of Studies that Illustrate the Importance of Transparency in Autism Research
A number of ASD and Hg studies, sponsored by entities with an apparent conflict of interest, appear to have arrived at questionable conclusions. Moreover, the authors of these studies have, unfortunately, failed to make their datasets available to others for further evaluation, exemplifying the need for transparency in autism research. As expressed by Patricia Baskin and Robert Gross (Baskin and Gross 2015) , editors of the journal Neurology, on the need for greater transparency in research in general: ''The responsibility for promoting greater openness in research falls not only to the individuals performing the work, but to the funders of the work (including government, foundation, and industry sponsors), institutions where the work is being done, and to journal editors and peer reviewers, who do the final check on the quality of the research before it is released to readers.'' The following examples illustrate this point. Verstraeten et al. (2000 Verstraeten et al. ( , 2003 In the late 1990s, in a study sponsored by the CDC, Thomas Verstraeten and colleagues (2000) ''categorized the cumulative ethyl-Hg exposure from [T]himerosal [-] containing vaccines after one month of life and assessed the subsequent risk of degenerative and developmental neurologic disorders and renal disorders before the age of six'' (Verstraeten et al. 2000, File 10 25 of 334) . The authors applied proportional hazard models adjusting for Health Management Organization, year of birth, and gender, and they excluded premature babies. The original reported results showed that the relative risk (RR) of developing a neurologic development disorder was 1.8 (95% confidence intervals [CI] 1.1-2.8) when comparing the highest exposure group at 1 month of age (cumulative dose [ 25 lg) to the unexposed group. Similarly, they ''…also found an elevated risk for the following disorders: autism (RR 7.6, 95% CI = 1.8-31.5), non-organic sleep disorders (RR 5.0, 95% CI = 1.6-15.9), and speech disorders (RR 2.1, 95% CI = 1.1-4.0)'' (Verstraeten et al. 2000, File 10 25 of 334) in the highest exposure group. These findings, presented to the Epidemic Intelligence Service Annual Conference, CDC in Atlanta, GA, in 2000, remained as an abstract (Verstraeten et al. 2000) and were never published as a full paper.
Subsequently published results from this study (Verstraeten et al. 2003 ) diverged from the aforementioned results presented in 2000 (Bernard 2004; Put Children First 2006) . The study published in 2003 concluded that ''No consistent significant associations were found between TCVs [Thimerosal-containing vaccines] and neurodevelopmental outcomes.'' (Verstraeten et al. 2003 (Verstraeten et al. , p. 1039 . When the dataset was requested by independent researchers (including M. Geier, one of the co-authors of the present article) through Representative Dave Weldon, M.D. (15th District, Florida) of the US Congress, it was unavailable and remains so. Explaining the unavailability of this dataset, the IOM stated: ''Analytic data files from some previously published VSD studies had not been archived in a standard manner, so it was difficult to respond expeditiously to requests to reanalyze published VSD [Vaccine Safety Datalink] studies.'' (Institute of Medicine 2005, p. 34) . In response to its own recommendation to make VSD datasets available to independent researchers, the IOM further stated, ''The committee recognizes that implementation of this recommendation probably can affect only future VSD studies because earlier versions of study datasets may not have been archived for current or completed studies.'' (Institute of Medicine 2005, p. 64).
Yau et al. (2014)
In 2013 Vincent Yau and colleagues, in conjunction with the California Department of Public Health, submitted a study to the Journal of Autism and Developmental Disorders, entitled, ''Prenatal and neonatal peripheral blood Hg levels and autism spectrum disorders.'' The conclusion stated by the authors was that the ''Results indicate that levels of total mercury in serum collected from mothers during midpregnancy and from newborn bloodspots were not significantly associated with risk of ASD.'' However, in Table 4 of the study, the geometric mean maternal serum Hg concentrations between the general population (0.32) and the ASD group (0.48) had a p value of 0.05. Thus, maternal serum blood Hg levels were significantly higher in the ASD group than in the general population, although the study authors failed to state this. The study was published later in the journal Environmental Research without addressing this issue. To date, the California Department of Public Health (CDPH), University of California at Davis (UC Davis), and Kaiser Permanente, as well as individual authors, have failed to release the dataset from the study for further evaluation despite receiving numerous requests for this information. The CDPH stated that they did not have the complete dataset and that they are required to make sure the data are destroyed after the studies are over (personal communication, Martin Kharrazi, CPDH, 6/25/2015) . UC Davis refused to release the dataset claiming, ''researcher's privilege, based upon a strong Constitutional interest in the right of scholars to conduct research without interference, an aspect to the academic freedom recognized as 'special concern of the First Amendment 
Uno et al. (2015)
In 2015, Yota Uno and colleagues published a study in the journal Vaccine investigating the relationship between the risk of ASD and early exposure to the combined Measles-Mumps-Rubella (MMR) vaccine, or exposure to Thimerosal from vaccinations in Japanese children. The authors concluded that there were no significant differences in the timing of MMR vaccination or Thimerosal dosage between children with ASD and controls for any age group. However, there was a statistical error that nullified the conclusions offered by the authors. This error was found in Table 2 at 24 months of age. From the values provided in Table 2 of the study, it was evident that the difference between cases and controls at 24 months was indeed statistically significant with a high degree of confidence. Thus, there was a statistically significant yet unacknowledged relationship between Thimerosal exposure and the risk of ASD. The journal Vaccine was notified of the error.
From the originally provided data, the following results were documented for Children, age 24 months: Unpaired t test mean of sample 1 from summary data = 804.2 (n = 189) mean of sample 2 from summary data = 632.1 (n = 224).
Assuming equal variances, the combined standard error = 71.8, df = 411, t = 2.40 one sided p = 0.0085 two sided p = 0.017, 95% confidence interval for difference between means = 30.88-313.32 power (for 5% significance) = 90.07%.
Assuming unequal variances, the combined standard error = 72.06, df = 394.17, t(d) = 2.39 one sided p = 0.0087 two sided p = 0.0174, 95% confidence interval for difference between means = 30.45-313.75 power (for 5% significance) = 66.35%. An unpaired t test assumes unequal variances and is a more conservative test.
When the journal Vaccine was made aware of the statistical error, it notified the authors. Following this notification, the authors changed the data values in their study (mean and standard deviation) for the controls in Table 2 at 24 months from 632.1 (715.1) to 676.8 (719.5). However, no explanation for the error or justification for the change was given. To date, the journal Vaccine and the study authors have refused requests to release the study dataset for further evaluation.
Although there was no response from any of the study authors, the journal Vaccine stated (in response to the notification of the error and the request for the dataset) that, ''Following the feedback from your group, the authors have made a minor correction to Table 2 and an acknowledgement thereof is made in the article. We are grateful for sharing your observations with us. As appropriate action has been undertaken, we now consider this matter to be resolved.'' (Personal communication, Alina Helsloot, Executive Publisher Immunology and Microbiology, Elsevier and Gregory Poland, Editor in Chief, Vaccine, 4/9/2015).
Summary and Conclusion
Historically, entities/industries with a vested interest in a product whose safety is in dispute have consistently used research to back their claims that a product is safe. The effects of a funding source on research outcomes have been examined, and it has been shown that industry or responsible entity affiliated studies are far more likely to yield outcomes favorable to that industry/entity (Boone et al. 2014) . When this conflict of interest influences research, the resulting scientific debate on products, toxicants, etc. can be confounded by misleading information. Indeed, this is precisely the outcome desired by the sponsors of such conflicted research (Brandt 2012; Bridbord and Hanson 2009; Brownell and Warner 2009) .
A conflict of interest in autism research has been noted, particularly when examining Hg exposure and the risk of ASD (DeSoto and Hitlan 2010). However, conflicts of interest in this debate are different from other cases because not only industries (e.g., the coal-burning industry and the pharmaceutical industry), but also public health institutions view this issue through the lens of their own potential culpability. Further complicating the matter is the fact that public health entities often control access to the relevant datasets. Indeed, a systematic examination of the research literature in the Hg-autism debate shows that research funded by these conflicted entities is more likely to yield conclusions favorable to that industry/ entity, that is, finding no relationship between Hg exposure and the risk of ASD.
Transparency in autism research is of utmost importance. The current examples of studies offering questionable conclusions clearly illustrate the need for openness and accountability. ASD is an issue of high national and international concern, where the stakes are high and researchers and policymakers need to be cognizant of the issue of conflicts of interest in autism research (DeSoto and Hitlan 2010) .
One way of achieving improved openness and transparency in autism research would be for authors, journals, and funding sources to require greater openness and data sharing. As mentioned, the responsibility for promoting greater openness in research falls not just to the authors, but to the funders, institutions, and journal editors (Baskin and Gross 2015) . The examples provided in this analysis suggest that some authors, journals, and institutions could improve in the area of helping to promote greater openness.
The Proceedings of the National Academy of Sciences of the United States of America (PNAS) has developed and adopted standards concerning the responsibilities of authorship in the biological sciences. It is referred to as the Uniform Principle for Sharing Integral Data and Materials Expeditiously or ''UPSIDE''. In October of 2001, a National Academies committee evaluated the responsibilities of authors to share data and materials referenced in their publications, the role of journals to impose requirements for data and material sharing, and whether a common set of requirements for sharing does or should exist (Cozzarelli 2001 (Cozzarelli , 2004 Cech 2003) . They established that authors are obligated to release data and materials to enable others to verify or replicate published findings. They stated that one ''upside'' to this is it keeps science honest (Cozzarelli 2001 (Cozzarelli , 2004 Cech 2003) . In an article by Nicholas R. Cozzarelli, Editor-in-Chief of PNAS, he described some of the comments of the board members and these comments may be relevant to the current discussion (Cozzarelli 2001) . Two of the comments are as follows:
I am one of the few people here who represents the private sector at this point, and I would love to be able to publish in prestigious journals and withhold the data. But I think it is wrong. Scientific journals should play no role in the protection of the private interests of authors, or in shielding data from the community. Protection is far afield of the mission of journals, and shielding is antithetical to it.
Identifying causative factors for ASD is already a challenging task for the scientific community, demanding the highest standards of openness and transparency. Any departure from these standards represents a disservice to all.
